Non-coding RNAs expression in SARS-CoV-2 infection: pathogenesis, clinical significance, and therapeutic targets [0.03%]
SARS-CoV-2感染中的非编码RNA表达：发病机制、临床意义和治疗靶点
Xiaoxing Liu,Wandi Xiong,Maosen Ye et al.
Xiaoxing Liu et al.
The coronavirus disease 2019 (COVID-19) pandemic has been looming globally for three years, yet the diagnostic and treatment methods for COVID-19 are still undergoing extensive exploration, which holds paramount importance in mitigating fut...
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study [0.03%]
基于PD-L1表达的纳武单抗联合或不联合含铂双药化疗作为可切除NSCLC的新辅助治疗：一项多中心开放性II期研究（CTONG1804）
Si-Yang Liu,Song Dong,Xue-Ning Yang et al.
Si-Yang Liu et al.
This prospective multicenter phase II study evaluated the clinical efficacy of neoadjuvant nivolumab-exclusive (N) and nivolumab-chemotherapy (N/C) combinations based on PD-L1 expression. Eligible patients exhibited resectable clinical stag...
Tau in the pancreas: understanding the link between type 2 diabetes mellitus and Alzheimer's disease [0.03%]
胰腺中的tau蛋白：2型糖尿病与阿尔茨海默病之间联系的理解
Wenlu Li,Steffen Tiedt,Eng H Lo
Wenlu Li
Gut liver brain axis in diseases: the implications for therapeutic interventions [0.03%]
肠道-肝脏-大脑轴在疾病中的作用：对治疗干预的启示
Mengyao Yan,Shuli Man,Benyue Sun et al.
Mengyao Yan et al.
Gut-liver-brain axis is a three-way highway of information interaction system among the gastrointestinal tract, liver, and nervous systems. In the past few decades, breakthrough progress has been made in the gut liver brain axis, mainly thr...
Managing type 2 diabetes: targeting a microbial enzyme as a novel treatment option [0.03%]
管理2型糖尿病：以靶向微生物酶作为新的治疗选择
Anikó Keller-Pintér,Tamás Korcsmáros,Tibor Vellai
Anikó Keller-Pintér
Going only half the way: cell cycle exit after the G1 restriction point [0.03%]
只走了一半路程：G1限制点后的细胞周期退出
Lisa Müller,Tony Gutschner,Mechthild Hatzfeld
Lisa Müller
SARS-CoV-2 Omicron subvariant BA.2.86: limited potential for global spread [0.03%]
SARS-CoV-2奥密克戎亚变体BA.2.86：全球传播潜力有限
Xinling Wang,Lu Lu,Shibo Jiang
Xinling Wang
Oncolytic adenoviruses expressing checkpoint inhibitors for cancer therapy [0.03%]
表达检查点抑制剂的溶瘤腺病毒用于癌症治疗
Daoyuan Xie,Yaomei Tian,Die Hu et al.
Daoyuan Xie et al.
Despite the remarkable success of immune checkpoint inhibitors (ICIs), primary resistance to ICIs causes only subsets of patients to achieve durable responses due to the complex tumor microenvironment (TME). Oncolytic viruses (OVs) can over...
Correction: Eosinophils promote pulmonary matrix destruction and emphysema via Cathepsin L [0.03%]
校正：Eosinophil通过Cathepsin L促进肺基质破坏和肺气肿的发展
Xia Xu,Tao Yu,Lingling Dong et al.
Xia Xu et al.
Jia Guo,Hanyi Zhang,Wenrui Lin et al.
Jia Guo et al.
Psoriasis is a common, chronic, and inflammatory skin disease with a high burden on individuals, health systems, and society worldwide. With the immunological pathologies and pathogenesis of psoriasis becoming gradually revealed, the therap...